These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35666353)

  • 1. The Role of Immunotherapy in the Treatment of Anal Cancer and Future Strategies.
    Jácome AA; Morris VK; Eng C
    Curr Treat Options Oncol; 2022 Aug; 23(8):1073-1085. PubMed ID: 35666353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).
    Kim S; Jary M; André T; Vendrely V; Buecher B; François E; Bidard FC; Dumont S; Samalin E; Peiffert D; Pernot S; Baba-Hamed N; El Hajbi F; Bouché O; Desrame J; Parzy A; Zoubir M; Louvet C; Bachet JB; Nguyen T; Abdelghani MB; Smith D; De La Fouchardière C; Aparicio T; Bennouna J; Gornet JM; Jacquin M; Bonnetain F; Borg C
    BMC Cancer; 2017 Aug; 17(1):574. PubMed ID: 28841909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Squamous cell anal carcinoma. What's next ?].
    Kim S; Spehner L; Cabel L; Bidard FC; Borg C
    Bull Cancer; 2021 Jan; 108(1):80-89. PubMed ID: 33423780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
    Kim S; Buecher B; André T; Jary M; Bidard FC; Ghiringhelli F; François É; Taieb J; Smith D; de la Fouchardière C; Desramé J; Samalin E; Parzy A; Baba-Hamed N; Bouché O; Tougeron D; Dahan L; El Hajbi F; Jacquin M; Rebucci-Peixoto M; Spehner L; Vendrely V; Vernerey D; Borg C
    BMC Cancer; 2020 Apr; 20(1):352. PubMed ID: 32334548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging and Experimental Agents for Anal Cancer: What is New?
    Farias JPF; Rangel da Silva MHC; Jácome AA
    J Exp Pharmacol; 2021; 13():433-440. PubMed ID: 33859504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy in advanced anal cancer: Is the beginning of a new era?
    Ciardiello D; Guerrera LP; Maiorano BA; Parente P; Latiano TP; Di Maio M; Ciardiello F; Troiani T; Martinelli E; Maiello E
    Cancer Treat Rev; 2022 Apr; 105():102373. PubMed ID: 35279535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies.
    Stouvenot M; Meurisse A; Saint A; Buecher B; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Smith D; Ghiringhelli F; Parzy A; de la Fouchardiere C; Almotlak H; Vienot A; Jacquin M; Taieb J; Nguyen T; Vernerey D; Borg C; Kim S
    Eur J Cancer; 2022 Feb; 162():138-147. PubMed ID: 34995900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological Checkpoint Blockade in Anal Squamous Cell Carcinoma: Dramatic Responses Tempered By Frequent Resistance.
    Jayakrishnan T; Yadav D; Huffman BM; Cleary JM
    Curr Oncol Rep; 2024 Aug; 26(8):967-976. PubMed ID: 38861124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
    Kim S; François E; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Ghiringhelli F; Parzy A; De La Fouchardiere C; Smith D; Deberne M; Spehner L; Badet N; Adotevi O; Anota A; Meurisse A; Vernerey D; Taieb J; Vendrely V; Buecher B; Borg C
    Lancet Oncol; 2018 Aug; 19(8):1094-1106. PubMed ID: 30042063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New approaches in palliative systemic therapy of anal squamous cell carcinoma.
    Lohynská R; Pechačová Z
    Klin Onkol; 2022; 35(3):190-194. PubMed ID: 35760571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic Therapies for Advanced Squamous Cell Anal Cancer.
    Sclafani F; Rao S
    Curr Oncol Rep; 2018 May; 20(7):53. PubMed ID: 29728940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Metastatic squamous cell carcinomas of the anal canal: Current management and prospects].
    Saint A; Evesque L; François É
    Bull Cancer; 2020; 107(7-8):792-799. PubMed ID: 32591138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress in the treatment of anal cancer: an overview of the latest investigational drugs.
    Yu J; Kim RD
    Expert Opin Investig Drugs; 2024 Feb; 33(2):145-157. PubMed ID: 38275174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma.
    Kim S; Jary M; Mansi L; Benzidane B; Cazorla A; Demarchi M; Nguyen T; Kaliski A; Delabrousse E; Bonnetain F; Letondal P; Bosset JF; Valmary-Degano S; Borg C
    Ann Oncol; 2013 Dec; 24(12):3045-50. PubMed ID: 24114858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The next generation of immunotherapy: keeping lung cancer in check.
    Somasundaram A; Burns TF
    J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States.
    Hale O; Patterson K; Lai Y; Meng Y; Li H; Godwin JL; Homet Moreno B; Mamtani R
    Clin Genitourin Cancer; 2021 Feb; 19(1):e17-e30. PubMed ID: 32826180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
    Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
    Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Telomerase CD4
    Spehner L; Kim S; Vienot A; François E; Buecher B; Adotevi O; Vernerey D; Abdeljaoued S; Meurisse A; Borg C
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32957741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
    Hayashi H; Nakagawa K
    Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.